Filtered By:
Management: Mergers and Aquisitions
This page shows you your search results in order of date.
Order by Relevance | Date
Total 13 results found since Jan 2013.
Advanced Medical Solutions Group plc: Acquisition of Sealantis
Winsford, UK, 31 January 2019: Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced wound care specialist company, today announces it has acquired Sealantis Limited ( “Sealantis”), a developer of an alginate-based tissue adhesive technology platform, for $US 25m (approximately £19m) in cash with royalties due until December 2027 on sales of any of its products that are currently in development.Overview of SealantisSealantis is an Israeli-based medical device company with a patent-protected alga-mimetic sealants technology platform with a wide range of potential surgical indications under developm...
Source: Medical Hemostat - February 1, 2019 Category: Medical Devices Authors: hemostatguy at gmail.com (hemostat guy) Source Type: blogs
BARDA adds $26m to Stratatech ’ s StrataGraft development deal
Mallinckrodt‘s (NYSE: MNK) Stratatech has won an additional $26 million in Project BioShield funding from the the U.S. Biomedical Advanced Research and Development Authority to support pediatric studies of its StrataGraft engineered skin tissue.
The funding will support continued development of the StrataGraft as a potential medical countermeasure for large-scale burn incidents, U.K.-based Mallinckrodt said. BARDA previously supplied funding to Stratatech during its Phase 3 trial of the Stratagraft in adults, which explored the safety and efficacy of the device in promoting autologous skin regeneration of complex ...
Source: Mass Device - October 17, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Featured Regenerative Medicine Wound Care Mallinckrodt Stratatech Corp. Source Type: news
Baxter inks partnership deal with International Society of Nephrology
Baxter (NYSE:BAX) said today it inked a partnership deal with the International Society of Nephrology looking to advance awareness and therapy for patients with chronic kidney disease, primarily in low and middle-income countries where the disease is growing the fastest.
In the collaborative partnership , Deerfield, Ill.-based Baxter and the ISN will look to support further therapy research and education about chronic kidney disease, while also looking to develop better care models at lower costs.
“ISN and Baxter’s collaboration aims to address the urgent and growing challenge kidney disease is causing healthcare ...
Source: Mass Device - May 2, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Baxter Source Type: news
Baxter closes $153m hemostat, sealant asset buy from Mallinckrodt
Baxter (NYSE:BAX) said today that it closed the $153 million acquisition of hemostat and sealant assets from Mallinckrodt Pharmaceuticals (NYSE:MNK).
Baxter announced in January its plan to acquire the stand-alone recombinant thrombin Recothrom and Preveleak surgical sealant for vascular reconstruction.
“We are excited to add both Recothrom and Preveleak to our portfolio of hemostats and sealants to offer surgeons additional options that address different situations when intraoperative bleeding can occur,” advanced surgery president Wil Boren said in prepared remarks. “Our top priority right now is wor...
Source: Mass Device - March 19, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Mergers & Acquisitions Surgical Vascular Wall Street Beat Baxter Mallinckrodt Source Type: news
Baxter acquires surgical products
Baxter International Inc., a global medical products company, said Monday that it will acquire two hemostat and sealant products from Mallinckrodt.It will acquire Recothrom Thrombin topical, the first and only stand-alone recombinant thrombin, and Preveleak Surgical Sealant, which is used in vascular reconstruction." Uncontrolled intraoperative bleeding can lead to a wide variety of clinical and economic complications for patients and hospitals. As a leading provider of advanced hemostats and sealants, Deerfield-based Baxter is focused on continually identifying solutions to help meet surgeons ' varying needs, " said Wil B...
Source: Medical Hemostat - January 9, 2018 Category: Medical Devices Authors: hemostatguy at gmail.com (hemostat guy) Source Type: blogs
Baxter buys Mallinckrodt ’ s Recothrom, Preveleak sealants for $153m
Baxter (NYSE:BAX) said today it inked an agreement with Mallinckrodt Pharmaceuticals (NYSE:MNK) to acquire its Recothrom and Preveleak hemostat and sealant products for approximately $153 million up front with a potential for contingent payments in the future.
Mallinckrodt’s Recothorm is a stand-alone recombinant thrombin-based product with indications as an aid to hemostasis to control oozing blood and minor bleeding from capillaries and small venules when control of bleeding by standard surgical techniques is ineffective or impractical.
The Preveleak sealant is designed to seal suture holes during surgical repai...
Source: Mass Device - January 8, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Surgical Baxter Mallinckrodt Source Type: news
Mallinckrodt Diversifies Hospital Growth Portfolio, Acquiring Three Commercial-Stage, Global Specialty Hemostasis Brands From The Medicines Company
CHESTERFIELD, United Kingdom, Dec. 18, 2015 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading global specialty biopharmaceutical company, today announced that it has entered into a purchase agreement with The Medicines Company (NASDAQ: MDCO) under which subsidiaries of Mallinckrodt plc will acquire a global portfolio of three commercial-stage topical hemostasis drugs – RECOTHROM® Thrombin topical (Recombinant), PreveLeak™ Surgical Sealant, and RAPLIXA™ (Fibrin Sealant) – for an initial payment of approximately $175 million, inclusive of existing inventory. Th...
Source: Medical Hemostat - December 19, 2015 Category: Medical Equipment Authors: hemostatguy at gmail.com (hemostat guy) Source Type: blogs
Z-Medica Bolsters Hemostatic Product Line with Acquisition of Novacol(R)
WALLINGFORD, Conn.--(Healthcare Sales & Marketing Network)--Z-Medica, a leading developer and marketer of hemostatic agents, today announced that they have signed a definitive agreement with TAUREON, headquartered in The Netherlands, to acquire Novacol®... Devices, AcquisitionsZ-Medica, TAUREON, Novacol, resorbable hemostat
Source: HSMN NewsFeed - May 5, 2014 Category: Pharmaceuticals Source Type: news
Z-Medica Bolsters Hemostatic Product Line with Acquisition of Novacol®
WALLINGFORD, CONN. — Z-Medica, a leading developer and marketer of hemostatic agents, today announced that they have signed a definitive agreement with TAUREON, headquartered in The Netherlands, to acquire Novacol®, a Class III resorbable hemostatic product.Novacol is currently sold in Europe and South Korea. Z-Medica will continue to support that marketing strategy while making plans to expand the product offering into other countries.“Given our QuikClot portfolio of hemostatic dressings, it was a natural fit for us to augment both our product line and our international presence with Novacol,” said Z-Medica’s Pre...
Source: Medical Hemostat - May 5, 2014 Category: Technology Consultants Authors: hemostatguy at gmail.com (hemostat guy) Source Type: blogs
Z-Medica Bolsters Hemostatic Product Line with Acquisition of Novacol ®
WALLINGFORD, CONN. — Z-Medica, a leading developer and marketer of hemostatic agents, today announced that they have signed a definitive agreement with TAUREON, headquartered in The Netherlands, to acquire Novacol®, a Class III resorbable hemostatic product. Novacol is currently sold in Europe and South Korea. Z-Medica will continue to support that marketing strategy while making plans to expand the product offering into other countries. “Given our QuikClot portfolio of hemostatic dressings, it was a natural fit for us to augment both our product line and our international presence with Novacol,” said Z-Medica...
Source: Medical Hemostat - May 4, 2014 Category: Medical Equipment Authors: hemostatguy at gmail.com (hemostat guy) Source Type: blogs
Arch Therapeutics offers $2.9M in private stock placement
Massachusetts-based Arch Therapeutics hopes to sell over 11 million shares to raise close to $3 million in support of its medical sealants and hemostasis products.Arch Therapeutics brings in nearly $3M in private stock placementArch Therapeutics launched a private placement fundraising effort, offering 11.4 million shares of common stock in hopes of raising $2.9 million.Wellesley, Mass.-based Arch Therapeutics develops medical sealants and hemostasis products for use during surgeries. The company's marquee device is the AC5 Surgical Hemostatic for minimally invasive and open surgical procedures.Arch is offering unnamed "in...
Source: Medical Hemostat - February 7, 2014 Category: Technology Consultants Authors: hemostatguy at gmail.com (hemostat guy) Source Type: blogs
Abyrx(TM), Inc. Announces Option to Acquire Haibo Biotechnology Institute's Soft Tissue Hemostat Technology Platform
IRVINGTON, N.Y., Jan. 27, 2014 -- (Healthcare Sales & Marketing Network) -- Abyrx, Inc., a privately-held therapeutic device company, today announced it has entered the soft tissue hemostasis market with an option to acquire for exclusive development, man... Devices, Surgery, AcquisitionsAbyrx, Haibo Biotechnology Institute, hemostasis, Soft Tissue Hemostat
Source: HSMN NewsFeed - January 27, 2014 Category: Pharmaceuticals Source Type: news
Medafor sells to Bard for $200 million, plus incentives that could add another $80 million.
Officials at Medafor Inc., a Brooklyn Center-based maker of a novel blood clotting product, said they’ve been looking for ways to enhance shareholder value — be it an initial public offering, new business relationships or just continuing organic growth. The one thing they weren’t looking for was a buyer, leaders said Monday.Then the folks at C.R. Bard Inc., a New Jersey-based medical equipment maker, came calling.Their offer — $200 million in cash now and up to $80 million more if revenue targets are hit in the next two years — proved too attractive to pass up, said Medafor CEO Gary Shope.Medafor on Monday announ...
Source: Medical Hemostat - August 20, 2013 Category: Technology Consultants Authors: hemostatguy at gmail.com (hemostat guy) Source Type: blogs
